<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02838199</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2016-16</org_study_id>
    <nct_id>NCT02838199</nct_id>
  </id_info>
  <brief_title>TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis</brief_title>
  <acronym>TRANSIT</acronym>
  <official_title>Prospective, Open Label, Multicenter, Dual Arm, Randomized Trial of TRANscatheter or SurgIcal Aortic Valve ReplacemenT in All-Comers With Severe Aortic Valve Stenosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine that Transcatheter aortic valve replacement (TAVR)
      with SAPIEN 3 is superior to traditional surgical aortic valve replacement(SAVR) with
      bio-prosthesis regarding the rate of all-cause mortality at 1 year in patients with
      symptomatic severe aortic valve stenosis.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2030</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>event rate of all-cause mortality</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>event rate of cardiovascular mortality</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of cardiovascular mortality</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of myocardial Infarction</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of myocardial Infarction</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of all Stroke and transient ischemic attack</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of all Stroke and transient ischemic attack</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of bleeding</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of bleeding</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of vascular access site and access-related complication</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of vascular access site and access-related complication</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of acute kidney injury</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of acute kidney injury</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of permanent pacemaker insertion</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of permanent pacemaker insertion</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of other TAVR-related complication</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
    <description>Conversion to open surgery Coronary obstruction Mitral valve apparatus damage or dysfunction Cardiac tamponade Endocarditis Valve thrombosis Valve malpositioning TAV-in-TAV deployment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of other TAVR-related complication</measure>
    <time_frame>31 days to the 1 year</time_frame>
    <description>Conversion to open surgery Coronary obstruction Mitral valve apparatus damage or dysfunction Cardiac tamponade Endocarditis Valve thrombosis Valve malpositioning TAV-in-TAV deployment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of prosthetic valve dysfunction</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
    <description>Prosthetic aortic valve stenosis Prosthesis-patient mismatch Prosthetic aortic valve regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of prosthetic valve dysfunction</measure>
    <time_frame>31 days to the 1 year</time_frame>
    <description>Prosthetic aortic valve stenosis Prosthesis-patient mismatch Prosthetic aortic valve regurgitation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of composite event for device success, early safety, clinical efficacy</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
    <description>Number of cases with following events ;
A. Device success
or
B. Early safety (At 30 days):
All-cause mortality, all stroke, life threatening bleeding, acute kidney injury, coronary obstruction requiring intervention, major vascular complication, valve-related dysfunction requiring repeat procedure.
or
C. Clinical efficacy (After 30 days):
All-cause mortality, all stroke, requiring hospitalization for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV, valve related dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of composite event for device success, early safety, clinical efficacy</measure>
    <time_frame>31 days to the 1 year</time_frame>
    <description>Number of cases with following events ;
A. Device success
or
B. Early safety (At 30 days):
All-cause mortality, all stroke, life threatening bleeding, acute kidney injury, coronary obstruction requiring intervention, major vascular complication, valve-related dysfunction requiring repeat procedure.
or
C. Clinical efficacy (After 30 days):
All-cause mortality, all stroke, requiring hospitalization for valve-related symptoms or worsening congestive heart failure, NYHA class III or IV, valve related dysfunction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of structural valve deterioration</measure>
    <time_frame>30 days or hospital discharge, whichever is longer</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of structural valve deterioration</measure>
    <time_frame>31 days to the 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA (New York Heart Association Functional Classification)</measure>
    <time_frame>30days and 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Valve area</measure>
    <time_frame>30days and 1 year</time_frame>
    <description>Aortic valve area (AVA) measured by 2D-transthoracic echocardiography using the continuity equation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>event rate of free from atrial fibrillation</measure>
    <time_frame>30days and 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>TAVR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcatheter aortic valve replacement with SAPIEN 3</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SAVR</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgical aortic valve replacement</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SAPIEN 3</intervention_name>
    <arm_group_label>TAVR</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>SAVR</intervention_name>
    <arm_group_label>SAVR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age must be at least 19 and less than 75 years old

          -  Severe aortic valve stenosis with echocardiographically derived criteria: mean
             gradient &gt; 40mmHg or jet velocity greater than 4.0 m/s AND an initial aortic valve
             area (AVA) of â‰¤ 0.8 cm2. Echocardiogram must be within 3 months of the date of the
             procedure

          -  Patient is symptomatic from his/her aortic valve stenosis, as demonstrated by NYHA
             class II or greater.

          -  The patient or guardian agrees to the study protocol and the schedule of clinical and
             angiographic follow-up, and provides informed, written consent, as approved by the
             appropriate Institutional Review Board/Ethical Committee of the respective clinical
             site.

        Exclusion Criteria:

          -  Life expectancy &lt;1 year due to medical illness

          -  Suspected Malignancy

          -  Inoperability evaluated by surgeon

          -  Concomitant severe coronary artery disease not amenable for percutaneous coronary
             intervention

          -  Concomitant severe mitral valve or significant aorta disease requiring surgery

          -  Active bacterial endocarditis within 6 months of procedure

          -  Leukopenia (WBC&lt;3000 cell/mL), acute anemia (Hgb&lt;8g/dL), thrombocytopenia (platelet &lt;
             50000 cell/mL)

          -  Intracardiac thrombus

          -  A known contraindication or hypersensitivity to all anticoagulation regimens, or
             inability to be anticoagulated for the study procedure.

          -  Native aortic annulus size &lt; 18 mm or &gt; 25 mm as measured by echocardiogram.

          -  Expectation that patient will not improve despite treatment of aortic stenosis

          -  Patients who are actively participating in another drug or device investigational
             study, which have not completed the primary endpoint follow-up period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Suck-jung Choo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 6, 2016</study_first_submitted>
  <study_first_submitted_qc>July 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>November 22, 2016</last_update_submitted>
  <last_update_submitted_qc>November 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>professor of medicine</investigator_title>
  </responsible_party>
  <keyword>Transcatheter aortic valve replacement</keyword>
  <keyword>TAVR</keyword>
  <keyword>TAVI</keyword>
  <keyword>SAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Aortic Valve Stenosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

